Lannett Reports Solid Fiscal 2016 First Quarter Results
--Net Sales of $106 Million, GAAP EPS OF $0.89, Adjusted EPS of $0.99--
PHILADELPHIA, Nov. 4, 2015 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2016 first quarter ended September 30, 2015.
For the fiscal 2016 first quarter, net sales increased to $106.4 million from $93.4 million in last year's first quarter. Gross profit was $77.4 million, or 73% of net sales, compared with $71.6 million, or 77% of net sales. Research and development expenses increased to $6.5 million from $6.4 million for the fiscal 2015 first quarter. Selling, general and administrative (SG&A) expenses were $15.5 million compared with $10.5 million. Acquisition-related expenses increased to $3.9 million from $70 thousand in the comparable prior-year period. Operating income was $51.4 million compared with $54.7 million. Net income attributable to Lannett was $33.2 million, or $0.89 per diluted share, compared with $34.9 million, or $0.94 per diluted share, for the fiscal 2015 first quarter.
On a Non-GAAP adjusted basis, gross profit was $77.8 million, or 73% of net sales, compared with $71.6 million, or 77% of net sales, for the fiscal 2015 first quarter. Adjusted SG&A expenses were $13.9 million compared with $10.5 million. Adjusted operating income increased to $57.3 million from $54.7 million for the prior year first quarter. Adjusted net income attributable to Lannett increased to $37.1 million, or $0.99 per diluted share, from $35.0 million, or $0.95 per diluted share, for the fiscal 2015 first quarter.
"A key driver of our strong first quarter performance was higher sales volumes across a number of therapeutic product categories," said Arthur Bedrosian, chief executive officer of Lannett. "We have now reported fifteen consecutive quarters in which net sales and adjusted EPS exceeded the comparable prior-year period.
"With respect to our acquisition initiatives, Silarx is proving to be a significant contributor to the company portfolio with two recent product approvals. Additionally, the pending Kremers Urban acquisition is on track and we anticipate closing the deal shortly."
Conference Call Information and Forward-Looking Statements
Later today, the company will host a conference call at 4:30 p.m. ET to review its results of operations for the fiscal 2016 first quarter ended September 30, 2015. The conference call will be available to interested parties by dialing 888-895-5271 from the U.S. or Canada, or 847-619-6547 from international locations, passcode 41121801. The call will be broadcast via the Internet at www.lannett.com. Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. A playback of the call will be archived and accessible on the same website for at least three months.
Discussion during the conference call may include forward-looking statements regarding such topics as, but not limited to, the company's financial status and performance, regulatory and operational developments, and any comments the company may make about its future plans or prospects in response to questions from participants on the conference call.
Use of Non-GAAP Financial Measures:
This news release contains references to Non-GAAP financial measures, including Adjusted net income attributable to the Company, and its components, as well as Adjusted earnings per diluted share, which are financial measures that are not prepared in conformity with United States generally accepted accounting principles (U.S. GAAP). The Company's management believes that the presentation of Non-GAAP financial measures provides useful supplementary information regarding operational performance, because it enhances an investor's overall understanding of the financial results for the Company's core business. Additionally, it provides a basis for the comparison of the financial results for the Company's core business between current, past and future periods. Non-GAAP financial measures should be considered only as a supplement to, and not as a substitute for or as a superior measure to, financial measures prepared in accordance with U.S. GAAP.
About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements, including, but not limited to, the anticipated closing of the Kremers Urban Pharmaceuticals acquisition whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, including products acquired in the Silarx transaction, Lannett's estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company's Form 10-K and other documents filed with the Securities and Exchange Commission from time to time. These forward-looking statements represent the company's judgment as of the date of this news release. The company disclaims any intent or obligation to update these forward-looking statements.
FINANCIAL SCHEDULES FOLLOW
|
LANNETT COMPANY, INC. |
||||||
|
CONSOLIDATED BALANCE SHEETS |
||||||
|
(In thousands, except share and per share data) |
(Unaudited) |
|||||
|
September 30, 2015 |
June 30, 2015 | |||||
|
ASSETS |
||||||
|
Current assets: |
||||||
|
Cash and cash equivalents |
$ 207,768 |
$ 200,340 | ||||
|
Investment securities |
14,890 |
13,467 | ||||
|
Accounts receivable, net |
107,216 |
91,103 | ||||
|
Inventories, net |
45,231 |
46,191 | ||||
|
Prepaid income taxes |
4,953 |
- | ||||
|
Deferred tax assets |
15,854 |
16,270 | ||||
|
Other current assets |
4,512 |
3,175 | ||||
|
Total current assets |
400,424 |
370,546 | ||||
|
Property, plant and equipment, net |
98,621 |
94,556 | ||||
|
Intangible assets, net |
28,903 |
29,090 | ||||
|
Goodwill |
141 |
141 | ||||
|
Deferred tax assets |
12,471 |
12,495 | ||||
|
Other assets |
2,441 |
1,938 | ||||
|
TOTAL ASSETS |
$ 543,001 |
$ 508,766 | ||||
|
LIABILITIES |
||||||
|
Current liabilities: |
||||||
|
Accounts payable |
$ 17,259 |
$ 19,195 | ||||
|
Accrued expenses |
6,675 |
4,928 | ||||
|
Accrued payroll and payroll-related expenses |
4,748 |
10,397 | ||||
|
Rebates payable |
11,458 |
7,553 | ||||
|
Income taxes payable |
- |
1,918 | ||||
|
Current portion of long-term debt |
137 |
135 | ||||
|
Total current liabilities |
40,277 |
44,126 | ||||
|
Long-term debt, less current portion |
839 |
874 | ||||
|
TOTAL LIABILITIES |
41,116 |
45,000 | ||||
|
Commitments and Contingencies |
||||||
|
STOCKHOLDERS' EQUITY |
||||||
|
Common stock($0.001 par value, 100,000,000 shares authorized; 36,896,482 and 36,783,381 shares issued; 36,362,052 and 36,264,585 shares outstanding at September 30, 2015 and June 30, 2015, respectively) |
||||||
|
37 |
37 | |||||
|
Additional paid-in capital |
242,025 |
236,178 | ||||
|
Retained earnings |
266,754 |
233,573 | ||||
|
Accumulated other comprehensive loss |
(311) |
(295) | ||||
|
Treasury stock(534,430 and 518,796 shares at September 30, 2015 and June 30, 2015, respectively) |
(6,988) |
(6,080) | ||||
|
Total Lannett Company, Inc. stockholders' equity |
501,517 |
463,413 | ||||
|
Noncontrolling interest |
368 |
353 | ||||
|
Total stockholders' equity |
501,885 |
463,766 | ||||
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ 543,001 |
$ 508,766 | ||||
|
LANNETT COMPANY, INC. | ||||
|
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) | ||||
|
(In thousands, except share and per share data) | ||||
|
Three months ended | ||||
|
September 30, | ||||
|
2015 |
2014 | |||
|
Net sales |
$ 106,433 |
$ 93,387 | ||
|
Cost of sales |
28,819 |
21,800 | ||
|
Amortization of intangibles |
187 |
20 | ||
|
Gross profit |
77,427 |
71,567 | ||
|
Operating expenses: |
||||
|
Research and development expenses |
6,528 |
6,363 | ||
|
Selling, general, and administrative expenses |
15,536 |
10,483 | ||
|
Acquisition-related expenses |
3,942 |
70 | ||
|
Total operating expenses |
26,006 |
16,916 | ||
|
Operating income |
51,421 |
54,651 | ||
|
Other income (loss): |
||||
|
Gain on sale of assets |
- |
20 | ||
|
Gain (loss) on investment securities |
(1,196) |
15 | ||
|
Interest and dividend income |
86 |
102 | ||
|
Interest expense |
(60) |
(38) | ||
|
Total other income (loss) |
(1,170) |
99 | ||
|
Income before income taxes |
50,251 |
54,750 | ||
|
Income tax expense |
17,055 |
19,800 | ||
|
Net income |
33,196 |
34,950 | ||
|
Less: Net income attributable to noncontrolling interest |
15 |
18 | ||
|
Net income attributable to Lannett Company, Inc. |
$ 33,181 |
$ 34,932 | ||
|
Earnings per common share attributable to Lannett Company, Inc. |
||||
|
Basic |
$ 0.91 |
$ 0.98 | ||
|
Diluted |
$ 0.89 |
$ 0.94 | ||
|
Weighted average common shares outstanding: |
||||
|
Basic |
36,310,653 |
35,597,931 | ||
|
Diluted |
37,414,724 |
36,972,646 | ||
|
LANNETT COMPANY, INC. | ||||||||||||
|
RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION | ||||||||||||
|
(In thousands, except share and per share data) | ||||||||||||
|
Three months ended |
Three months ended | |||||||||||
|
September 30, |
September 30, | |||||||||||
|
GAAP |
Non-GAAP |
GAAP |
Non-GAAP | |||||||||
|
Reported |
Adjustments |
Adjusted |
Reported |
Adjustments |
Adjusted | |||||||
|
2015 |
2015 |
2015 |
2014 |
2014 |
2014 | |||||||
|
Net sales |
$ 106,433 |
$ - |
$ 106,433 |
$ 93,387 |
$ - |
$ 93,387 | ||||||
|
Cost of sales |
28,819 |
(140) |
(a) |
28,679 |
21,800 |
- |
21,800 | |||||
|
Amortization of intangibles |
187 |
(187) |
(b) |
- |
20 |
(20) |
(b) |
- | ||||
|
Gross profit |
77,427 |
327 |
77,754 |
71,567 |
20 |
71,587 | ||||||
|
Operating expenses: |
||||||||||||
|
Research and development expenses |
6,528 |
- |
6,528 |
6,363 |
- |
6,363 | ||||||
|
Selling, general, and administrative expenses |
15,536 |
(1,652) |
(c) |
13,884 |
10,483 |
- |
10,483 | |||||
|
Acquisition-related expenses |
3,942 |
(3,942) |
(d) |
- |
70 |
(70) |
(d) |
- | ||||
|
Total operating expenses |
26,006 |
(5,594) |
20,412 |
16,916 |
(70) |
16,846 | ||||||
|
Operating income |
51,421 |
5,921 |
57,342 |
54,651 |
90 |
54,741 | ||||||
|
Other income (loss) |
(1,170) |
- |
(1,170) |
99 |
- |
99 | ||||||
|
Income before income tax |
50,251 |
5,921 |
56,172 |
54,750 |
90 |
54,840 | ||||||
|
Income tax expense |
17,055 |
2,034 |
(e) |
19,089 |
19,800 |
33 |
(e) |
19,833 | ||||
|
Net income |
33,196 |
3,887 |
37,083 |
34,950 |
57 |
35,007 | ||||||
|
Less: Net income attributable to noncontrolling interest |
15 |
- |
15 |
18 |
- |
18 | ||||||
|
Net income attributable to Lannett Company, Inc. |
$ 33,181 |
$ 3,887 |
$ 37,068 |
$ 34,932 |
$ 57 |
$ 34,989 | ||||||
|
Earnings per common share attributable to Lannett Company, Inc. |
||||||||||||
|
Basic |
$ 0.91 |
$ 1.02 |
$ 0.98 |
$ 0.98 | ||||||||
|
Diluted |
$ 0.89 |
$ 0.99 |
$ 0.94 |
$ 0.95 | ||||||||
|
Weighted average common shares outstanding: |
||||||||||||
|
Basic |
36,310,653 |
36,310,653 |
35,597,931 |
35,597,931 | ||||||||
|
Diluted |
37,414,724 |
37,414,724 |
36,972,646 |
36,972,646 | ||||||||
|
(a) |
To exclude amortization of a fair value step-up in inventory related to the acquisition of Silarx Pharmaceuticals, Inc. | |||||||||||
|
(b) |
To exclude amortization of purchased intangible assets primarily related to the acquisition of Silarx Pharmaceuticals, Inc. | |||||||||||
|
(c) |
To exclude separation payments associated with the retirement of an executive officer | |||||||||||
|
(d) |
To exclude acquisition-related expenses primarily related to the pending acquisition of Kremers Urban Pharmaceuticals Inc. and the completed acquisition of Silarx Pharmaceuticals Inc. | |||||||||||
|
(e) |
The tax effect of the pre-tax adjustments included above at applicable tax rates | |||||||||||
|
Contact: |
Robert Jaffe |
|
Robert Jaffe Co., LLC | |
|
(424) 288-4098 |
Logo - http://photos.prnewswire.com/prnh/20150417/199461LOGO
SOURCE Lannett Company, Inc.